TNF and infection: These findings collectively suggest that Anakinra exhibits moderate anti-inflammatory effects with long-term joint protection, making it a viable option for patients with inadequate responses to TNF-α inhibitors or those requiring infection-safe therapies (Scott et al., 2016).